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Abstract
Objective: Onset of multiple sclerosis (MS) occurs in childhood for approximately 5% of cases (pediatric MS, or ped-MS). Epigenetic influences are
strongly implicated in MS pathogenesis in adults, including the contribution
from microRNAs (miRNAs), small noncoding RNAs that affect gene expression
by binding target gene mRNAs. Few studies have specifically examined miRNAs
in ped-MS, but individuals developing MS at an early age may carry a relatively
high burden of genetic risk factors, and miRNA dysregulation may therefore
play a larger role in the development of ped-MS than in adult-onset MS. This
study aimed to look for evidence of miRNA involvement in ped-MS pathogenesis. Methods: GWAS results from 486 ped-MS cases and 1362 controls from
the U.S. Pediatric MS Network and Kaiser Permanente Northern California
membership were investigated for miRNA-specific signals. First, enrichment of
miRNA-target gene network signals was evaluated using MIGWAS software.
Second, SNPs in miRNA genes and in target gene binding sites (miR SNPs)
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were tested for association with ped-MS, and pathway analysis was performed
on associated target genes. Results: MIGWAS analysis showed that miRNA-target gene signals were enriched in GWAS (P = 0.038) and identified 39 candidate biomarker miRNA-target gene pairs, including immune and neuronal
signaling genes. The miR-SNP analysis implicated dysregulation of miRNA
binding to target genes in five pathways, mainly involved in immune signaling.
Interpretation: Evidence from GWAS suggests that miRNAs play a role in pedMS pathogenesis by affecting immune signaling and other pathways. Candidate
biomarker miRNA-target gene pairs should be further studied for diagnostic,
prognostic, and/or therapeutic utility.

Introduction
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system and a leading
cause of neurological disability in young adults. MS is
typically diagnosed between the ages of 20 and 40, but it
is estimated that up to 5% of all cases experience their
first symptoms before the age of 18.1,2 While pediatriconset MS (ped-MS) and adult MS presentation largely
overlap, disease course in children is almost exclusively
relapsing-remitting, with a higher relapse rate, and a
longer time to development of secondary progressive MS
and disability.2–4
MS is thought to result from a complex interplay of
genetic, epigenetic, and environmental risk factors.5
MicroRNAs (miRNAs) are epigenetic factors that have
been investigated in MS, and over 170 miRNAs have been
found to be differentially expressed in various tissues in
either adult-onset MS or experimental autoimmune
encephalomyelitis (EAE) in mice.6–13 One study specifically compared miRNA expression levels in ped-MS cases
to pediatric controls, and 12 upregulated and one downregulated miRNA were reported.14 miRNAs are short
(~22 nucleotides) noncoding RNAs that usually downregulate gene expression by binding to specific sequences of
messenger RNA (mRNA) transcripts, targeting them for
degradation and blocking protein translation, though different miRNA functions have also been reported.15 Target
sites generally lie in the 3’ untranslated regions (3’ UTRs)
of mRNAs, but binding in other regions is known to
occur.16 Because each miRNA can target hundreds of
genes, and any gene can be regulated by multiple miRNAs, they have the potential to influence entire networks
of genes at once.
Single-nucleotide polymorphisms (SNPs) in and
around miRNA genes have been associated with a number of autoimmune diseases, including MS.17 These
miRNA SNPs can disrupt normal gene regulatory functions by affecting miRNA expression levels and processing, but SNPs in the target-binding sites of mRNAs can
also impact the normal function of miRNAs. Strategies to
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examine target gene SNPs in addition to miRNA gene
SNPs have recently been developed and have implicated
specific miRNAs and target genes in the development of
autoimmune and other diseases.18–21
This study examined evidence of miRNA involvement
in ped-MS susceptibility in two ways. First, genomewide association study (GWAS) results were tested for
enrichment of signals in miRNA-target gene networks
utilizing MIGWAS software.21,22 Second, a miR-SNP
association study was performed, and pathway analysis
was used to characterize target genes harboring miRSNPs associated with ped-MS. We define miR-SNP as a
SNP that is either (1) located in a gene that codes for
a miRNA, or (2) located in a miRNA-binding site of a
target gene.

Methods
Study participants
The study participants have been previously described,23
but now include additional ped-MS cases with same
inclusion/exclusion criteria. Additionally, only participants
who were genotyped using an Illumina BeadChip array
were included in this study. Briefly, patients with onset of
MS or clinically isolated syndrome (CIS) with two silent
MRI lesions suggestive of early MS before the age of 18
(n = 432) were enrolled through the U.S. Network of
Pediatric MS Centers.3 Additional adult cases with onset
prior to age 18 (n = 68) were recruited retrospectively
from the Kaiser Permanente Northern California (KPNC)
membership. All cases were confirmed to have MS using
established diagnostic criteria.24,25
Pediatric controls (n = 208) were enrolled through the
U.S. Network of Pediatric MS Centers.3 Adult controls
(n = 894) without a diagnosis of MS, optic neuritis,
transverse myelitis, or demyelinating disease confirmed
through electronic medical records were recruited from
KPNC and enrolled. A second set of previously
described26 female adult controls (n = 268) with no prior
history of autoimmune disease who were recruited as part
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of the University of California San Francisco MotherChild Immunogenetic Study were also included.

Data collection
DNA from participants was purified from either whole
blood or saliva samples. Genotyping was performed using
Illumina Infinium 660K and Human Omni Express BeadChip arrays. Genotype data were merged into a single
dataset and processed using PLINK 1.9.27 SNPs with a
minor allele frequency (MAF) <1% or success rate <90%
and samples with >10% failed genotype calls were
removed from analysis. To reduce confounding due to
population stratification, analyses were restricted to white
individuals, defined as having >=80% European ancestry
identified using SNP weights for European, West African,
East Asian, and Native American ancestral populations.28
Related individuals were identified, and only one randomly chosen person in any related group was retained
for analysis, with the exception that cases were preferentially retained in instances where cases and controls were
related. Classical multidimensional scaling (MDS) was
used to visualize study population ancestry (Figure S1)
and include as covariates in subsequent statistical analyses. Five outlier samples were removed from analysis.
SNP imputation was performed with reference haplotypes
from Phase 3 of the 1000 Genomes Project29 using SHAPEIT2 and IMPUTE2.30 Genotypes were called using the
default hard-call threshold of 90% using PLINK. Imputed
SNPs with info score <0.3, with MAF <1%, with genotype
call rate <90%, or not in Hardy–Weinberg equilibrium
(HWE) among controls (P < 0.00001) were removed. The
final imputed dataset consisted of 7 570 644 autosomal
SNPs, of which 42 277 lay within the major histocompatibility complex (MHC) region chr6:29570005-33377657 in
GRCh37/hg19, spanning genes GABBR1 to KIFC1.31 Presence of the HLA-DRB1*15:01 allele, the strongest genetic
risk factor for MS, was determined for each participant
using the tag SNP rs3135388.32 There were 486 cases and
1362 controls in the final dataset. Study protocols were
approved by all institutions, and informed consent or
assent was obtained from all participants, as previously
described.23

Statistical analyses—miRNA-target gene
network enrichment in GWAS (MIGWAS)
Genome-wide association tests were performed on all
autosomal SNPs outside of the MHC using logistic
regression and additive genetic models in PLINK. Models
included the first three MDS components to adjust for
residual confounding by population stratification. Enrichment of miRNA-target gene network signals in the GWAS
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results was evaluated using MIGWAS software.21,22
Briefly, MIGWAS takes GWAS P-values as input, selects
the lowest P-value per miRNA and target gene, and, for
each of 179 different tissues with available miRNA expression data from FANTOM5,33 identifies the number of
miRNA-target gene pairs that satisfy the following conditions: both the miRNA and the target gene are associated
with the outcome (P < 0.01), there is a high binding
score prediction for the pair, and the miRNA is highly
and specifically expressed in the tissue. Enrichment of
miRNA-target gene signal is estimated by permuting
GWAS P-values 20 000 times and recomputing the number of miRNA-target gene pairs that satisfy the conditions
to obtain an empirical null distribution of that number.
A P-value for enrichment is then reported for each tissue,
as well as an overall enrichment P-value that does not
take tissue expression into consideration is also reported.
Enrichment P-values of 0.05 or lower were considered
significant. Candidate biomarker miRNA-target gene pairs
are also reported, and are defined as pairs where both the
miRNA and target gene are nominally associated with the
outcome (P < 0.01) and the miRNA-target gene binding
prediction score is in the top one percentile of all pairs.22

Statistical analyses—miR-SNP association
miR-SNPs were tested separately for association with pedMS. miR-SNPs in miRNA genes were identified using version 21 high-confidence annotations from the miRBase
database.34 Coordinates for 1877 miRNA genes were converted from build 38 to build 37 using the UCSC Genome Browser liftOver tool35 and intersected with imputed
SNPs in the ped-MS dataset using BEDTools,36 resulting
in 267 miR-SNPs outside of the MHC and 8 within the
MHC. miR-SNPs in predicted target-binding sites in the
3’ UTRs of protein-coding genes were identified using the
MirSNP database18 and version 3.0 of the PolymiRTS
database.19 SNPs in predicted target regions from either
database were intersected with the ped-MS dataset, resulting in 51 725 target region miR-SNPs outside of the
MHC and 586 miR-SNPs within the MHC.
Each miR-SNP was tested for association with ped-MS
using the same logistic regression models as in the GWAS
analysis, with the exception that models for miR-SNPs
within the MHC also included the HLA-DRB1*15:01 tag
SNP as a covariate. P-values in each category of association tests—miRNA gene SNPs or target gene SNPs,
within or outside of the MHC—were adjusted separately
for multiple hypothesis testing using the Benjamini–
Hochberg procedure to control the false discovery rate.37
A threshold of 0.05 was used to determine significance. In
an effort to reduce the statistical burden of multiple
hypothesis tests, several sets of candidate mir-SNPs were
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considered separately: 897 miR-SNPs in the 3’UTRs of
genes proximal to 200 non-MHC loci identified in the
latest adult-onset MS genome-wide association study;38
1063 miR-SNPs experimentally supported by crosslinking,
ligation, and sequencing of hybrids (CLASH) experiments, including in noncanonical binding sites and nonprotein-coding genes;16 19 516 miR-SNPs predicted in
the polymiRTS database to either create a new miRNAbinding site or disrupt a conserved miRNA-binding site,
with a context+ score difference of less than 0.15 (more
negative scores indicate increased confidence that miRNA
binding is disrupted); and one miR-SNP in the 3’ UTR of
the HLA-DRB1 gene.
Pathway analysis of target genes with mir-SNPs that
was nominally associated with ped-MS at P < 0.01 in the
main association analysis was conducted using
PANTHER.39 Statistical overrepresentation tests were performed using a background list of only protein-coding
genes. Each of nine available annotation datasets in the
“PANTHER,” “GO,” and “Reactome” pathways were
tested using Fisher’s Exact test with FDR multiple test
correction.

Results
Characteristics of study participants are summarized in
Table 1. Average age of onset for ped-MS cases was
14.3 years, and cases had more copies of the HLADRB1*15:01 allele than controls, as expected. When plotted with HGDP reference populations, cases, and controls
clustered together near European individuals (Figure S1).

miRNA-target gene network enrichment in
GWAS (MIGWAS)
Enrichment of miRNA-target gene network signals was
observed in the ped-MS GWAS results for 25 different

Table 1. Characteristics of ped-MS case and control individuals in the
miR-SNP association study

N
Sex
Female
Male
Age of onset
Copies HLA-DRB1*15:01 allele
0
1
2

Ped-MS cases

Controls

486

1362

362 (74)
124 (26)
14.3 (3.2)

1122 (82)
240 (18)
–

250 (51)
194 (40)
42 (9)

1005 (74)
334 (24)
23 (2)

Table values are mean (SD) for continuous variables or n (%) for categorical variables.
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tissues (P < 0.05) as well as overall, without considering
tissue-specific miRNA expression (P = 0.038). Results are
summarized in Table 2. MIGWAS identified 39 candidate
biomarker miRNA-target gene pairs comprised of 16
unique miRNAs and 37 unique genes (Table 3).

miR-SNP association
After adjusting P-values for multiple hypothesis testing, no
miR-SNPs were significantly associated with ped-MS in the
genome-wide analyses at FDR < 0.05. There were 255 target genes with 3’ UTR miR-SNPs associated at P < 0.01 in
the genome-wide analysis that were used as input for
Table 2. Tissues enriched for miRNA-target gene network signals
(P < 0.05) in ped-MS GWAS results in the MIGWAS analysis

Tissue

P-value

Fold
change

MIGWAS
tissue category

Keratinized cell of the oral
mucosa
Human spinal cord—adult
sample
Epithelial cell of amnion
Preadipocyte
Amnion mesenchymal stem cell
Epithelial cell of alimentary
canal
Synovial cell
Epithelial cell of esophagus
Acinar cell of sebaceous gland
Mast cell
Nonpigmented ciliary epithelial
cell
Tracheal epithelial cell
Smooth muscle cell of the
internal thoracic artery
All (tissue-na€ıve test)
Extraembryonic cell
Human renal cortical epithelial
cell sample
Pericyte cell
Hair follicle dermal papilla cell
Mesangial cell
Keratinizing barrier epithelial cell
Gingival epithelial cell
CD14-positive CD16-negative
classical monocyte
Exocrine cell
Epidermal cell
Omentum preadipocyte
Keratinocyte

0.002

4.07

gastrointestinal

0.011

2.61

brain

0.014
0.020
0.020
0.023

2.99
2.42
2.74
2.79

fetal
fat
fetal
gastrointestinal

0.025
0.026
0.027
0.029
0.031

2.25
2.28
2.64
2.49
2.13

joint
gastrointestinal
fat
immune
skin

0.033
0.035

2.59
2.14

lung
vascular

0.038
0.036
0.039

1.68
2.42
1.79

fetal
kidney

0.041
0.041
0.043
0.043
0.043
0.044

2.02
2.46
2.03
2.54
1.86
2.30

others
skin
kidney
others
gastrointestinal
immune

0.045
0.046
0.047
0.050

2.42
2.37
2.25
2.43

others
others
fat
skin

P-values and fold changes are for enrichment of the number of
miRNA-target gene pairs associated with ped-MS (where the pair has
a high predicted binding score and the miRNA is highly expressed in
the tissue) compared to the empirical null distribution of the number
of such pairs.
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Table 3. Candidate biomarker miRNA-target gene pairs associated
with ped-MS in MIGWAS

miRNA

Genes

hsa-miR-141
hsa-miR-197

CD80, THAP5
CD109, TSEN2

hsa-miR-200c

SLC35B4

hsa-miR-21

C11orf70, PLAA

hsa-miR-3128
hsa-miR-3188
hsa-miR-3605

CBL, SCLY
PRSS12
ARL6IP6

hsa-miR-4277
hsa-miR-4294
hsa-miR-4498
hsa-miR-4649
hsa-miR-587
hsa-miR-599

ZNF286B
SLC37A4
NCS1, RAB35
HYOU1
PRKRIR, UTP18
PAPPA

hsa-miR-608

ADPRH, CD109,
CIITA, COX10,
CYB561D1, EHD2,
GAST, GLIS2,
HYOU1, NTSR1,
PHF19, PIWIL3, PXN,
SNAI1, SYNJ2BP,
TFAP4, ZSCAN20
TANC2
EIF5A2, ERP29

hsa-miR-744
hsa-miR-875

Known miRNA expression
associations in MS

Decreased in T cells of
patients treated with IFN-b6
hsa-miR-200c increased in
white matter7; hsa-miR200a and hsa-miR-200b
decreased in B cells7; hsamiR-200a decreased in
whole blood8
Increased in white matter7;
decreased in peripheral
blood of ped-MS cases14

Increased in peripheral blood
of ped-MS cases14

Increased in PBMCs6 and
decreased in B cells7

Increased in PBMCs6

Pairs are candidate biomarkers if both the miRNA and target gene are
nominally associated with ped-MS (P < 0.01) and the miRNA-target
gene binding prediction score is in the top one percentile of all pairs.
The last column indicates previously observed MS associations in
miRNA expression studies. The “hsa-” prefix in the miRNA names
stands for homo sapiens.

pathway analyses. These genes were overrepresented in five
pathways in PANTHER (Table 4). Among the candidate
miR-SNP sets, only one CLASH-supported miR-SNP,
rs61075345 in the third exon of TVP23B, was associated
with ped-MS (P = 4.59 9 10 05, FDR = 0.047).

Discussion
In this study, evidence that miRNAs are involved in pedMS pathogenesis was sought using two different
approaches that utilized genetic data from the largest
population of ped-MS cases gathered to date.

The MIGWAS method identified enrichment of
miRNA-target gene networks in ped-MS GWAS results,
and identified tissues in which miRNAs involved in those
networks are known to be highly expressed. Tissues
included gastrointestinal, brain, fetal, fat, joint, immune,
lung, vascular, skin, kidney, and other tissues (Table 2).
While it is true that immune and central nervous system
tissues have clear roles in MS and are generally prioritized
first for study, there is evidence that processes starting in
other tissues may play a role in triggering MS and also
warrant investigation. For instance, smoking is hypothesized to exert its effect on MS risk primarily through irritation and inflammation of lung tissue, which in turn
likely trigger (possibly autoreactive) immune responses.5
The highest enrichment observed in this ped-MS study
was in a gastrointestinal tissue, keratinized cells of the oral
mucosa, and gastrointestinal tissues were overrepresented
in these results: four of the seven gastrointestinal tissues
tested were enriched for miRNA-target gene network signals. Evidence that miRNA dysregulation could specifically be occurring in gastrointestinal tissues is notable
because there is existing evidence of a bidirectional relationship between MS and the gut microbiome, where
aberrant gut microbiomes found in MS patients contribute to a proinflammatory state, and the autoreactive
immune systems of MS patients shape the gut microbiome.40
Several genes identified in the MIGWAS candidate biomarker target-gene pairs are involved in immune signaling and activation (Table 3) according to RefSeq
annotations,41 and are therefore particularly promising
targets of future research into the role miRNAs play in
ped-MS development. CIITA is a “master regulator” of
class II HLA gene expression, and CD80 is a T-cell membrane receptor that provides the costimulatory signal necessary for T-cell activation. CD109 is expressed in
activated T cells and regulates transforming growth factor
beta signaling. CBL is an enzyme required for targeting
substrates for degradation by the proteasome and is a
negative regulator of many signaling pathways triggered
by activation of cell surface receptors. TFAP4 is a transcription factor that activates both viral and cellular
genes. Two other MIGWAS genes with plausible roles in
ped-MS pathogenesis affect neuronal differentiation and
signaling. GLIS2 is widely expressed at low levels in the
neural tube and peripheral nervous system and is thought
to promote neuronal differentiation, and NCS1 modulates
synaptic transmission and synaptic plasticity and is
expressed predominantly in neurons. Three genes identified by MIGWAS are involved in protein folding and
homeostasis in the endoplasmic reticulum (ER), which is
notable because the ER lumen cellular component was
also identified in the miR-SNP pathway analysis. The ER
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Table 4. Pathways in which the 255 protein-coding genes containing miR-SNPs associated with ped-MS (P < 0.01) are statistically overrepresented

Pathway name (PANTHER
annotation source)

# Protein-coding
genes in pathway

# Expected
in 255
ped-MS
genes

# Found
in 255
ped-MS
genes

P-value
(FDR)

Ped-MS genes in pathway

Histamine H1 Receptor mediated
signaling (PANTHER Pathway)
5-HT2 type receptor mediated
signaling (PANTHER Pathway)
MHC Protein Complex
(GO Cellular Component)
Integral component of lumenal
side of endoplasmic reticulum
membrane (GO Cellular Component)
Interferon gamma signaling
(Reactome Pathway)

43

0.58

5

0.035

GNG4, PLCB3, PLCG2, PRKCB, PRKCI

66

0.86

6

0.064

PLCB3, PRKCI, PLCG2, GNG4, PRKCB, SLC18A2

25

0.34

5

0.085

HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-A, HLA-G

28

0.38

5

0.046

HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-A, HLA-G

90

1.21

9

0.014

HLA-DPB1, TRIM14, HLA-DQB1, HLA-DRA, HLA-A,
TRIM26/AFP, TRIM10, HLA-G, CIITA

For each pathway, the total number of protein-coding genes in the pathway is given, followed by the number of those genes expected by chance
to be found among the 255 ped-MS associated protein-coding genes, the actual number found, the P-value for statistical overrepresentation (adjusted for multiple hypothesis tests), and the list of ped-MS associated genes in the pathway.

lumen is where class I and II HLA proteins are assembled,42 and stress in the ER caused by accumulation of
misfolded proteins (the “unfolded protein response” or
UPR) is associated with a number of inflammatory diseases, including MS.43 Of the MIGWAS-identified genes,
HYOU1 is thought to play an important role in protein
folding and secretion in the ER. ERP29 localizes to the
lumen of the ER and is involved in the processing of
secretory proteins. SLC37A4 regulates transport from the
cytoplasm to the lumen of the ER to maintain glucose
homeostasis and plays a role in calcium sequestration in
the ER lumen. Collectively, the genes in the 39 miRNAtarget gene pairs suggest that miRNAs could be affecting
ped-MS through many mechanisms, including immune
signaling and activation, neuronal differentiation and signaling, and protein folding in the ER. Finally, it is notable
that expression differences in five of the 16 candidate
miRNAs identified by MIGWAS, hsa-mir-197, hsa-mir200c, hsa-mir-21, hsa-mir-599, and hsa-mir-744, have
been associated with MS or EAE in previous studies,6,7
and two of them, hsa-miR-21 and hsa-miR-3605, were
differentially expressed in ped-MS cases specifically
(though hsa-miR-21 failed a subsequent validation
assay).14 A follow-up to the ped-MS expression study
found that six of the 13 confirmed ped-MS-associated
miRNAs were also differentially expressed in adults,44 but
hsa-miR-3605 was not among them, suggesting that it
could be a biomarker specific to ped-MS.
In the miR-SNP analysis, the single CLASH-supported
miR-SNP associated with ped-MS resides in the TVP23B
gene, which codes for a membrane protein associated
with diabetic retinopathy.45 It is not immediately clear
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how it may play a role in ped-MS pathogenesis. However,
statistical overrepresentation tests of top miR-SNP hits
yielded two receptor-mediated signaling pathways with a
more evident relationship with ped-MS. Five genes in the
histamine H1 receptor pathway were found to have pedMS-associated miR-SNPs (Table 4). Histamine is a ubiquitous compound in human tissues that acts as a neurotransmitter and that is involved in inflammatory
responses that act through four different receptors, H1H4. It is thought that the proinflammatory effects of histamine act through H1 receptors.46 Many of the same
genes are also involved in the 5-HT2 type receptor mediated signaling pathway. 5-HT2 is a subtype of serotonin
receptors. Similar to histamine, serotonin is a signaling
molecule with wide-ranging effects that acts as both a
neurotransmitter and a hormone. The 5-HT2 class of hormone receptors is expressed on several immune cell
types.47 Our results suggest that dysregulation of genes
involved in these signaling pathways by miRNAs increases
ped-MS risk.
The other three pathways identified in the miR-SNP
analysis each encompass many of the same genes, including several genes encoded in the MHC (Table 4). Five
class I and II HLA genes associated with ped-MS are in
the MHC protein complex (GO cellular component). These
genes code for proteins that present antigens to T cells,
and variants in antigen-presenting genes are the first-documented and strongest genetic risk factors for MS.5,38 The
same five HLA genes are part of the integral component of
the luminal side of endoplasmic reticulum (ER) membrane
(GO Cellular Component). Of note, the genes identified in
the miR-SNP analysis are different from those identified
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in the MIGWAS analysis, but both methods point to dysregulation of processes in the ER. The interferon gamma
(IFN-c) signaling pathway contains a total of nine pedMS-associated genes. The role of IFN-c in MS has been
extensively studied, and, similar to histamine and serotonin, it can have detrimental or beneficial effects on MS
depending on where and when it is active.48 Our miRSNP analysis findings indicate that aberrant regulation by
miRNAs of genes in the MHC protein complex, genes on
the inner part of the ER lumen, or genes involved in
IFN-c signaling (which are not mutually exclusive genes),
could be contributing to ped-MS pathogenesis.
This study had some limitations. It is possible that the
SNPs identified in the MIGWAS and miR-SNP studies do
not affect ped-MS via miRNA function but instead are
associated due to linkage disequilibrium with SNPs acting
by other mechanisms. Another issue is that miRNA-target
binding prediction is imperfect, and therefore some of the
miRNAs may not actually act on the genes identified in
MIGWAS, and some of the miR-SNPs tested may not in
reality impact miRNA function. Because the study was
restricted to a white population, results may not be generalizable, and miRNA associations that exist in other nonwhite populations may have been missed.
An important strength of this study is that it utilized the
largest study population thus far for ped-MS, which is a
rare disease, and therefore difficult to study. Furthermore,
cases were ascertained by a panel of pediatric MS specialists. Only samples genotyped on Illumina microarrays were
utilized, minimizing the possibility of imputation bias, and
rigorous quality control of microarray data was applied.
By assessing P-values of SNPs in miRNA and target genes
at the same time, and by including miRNA expression
data, MIGWAS was able to detect signals that may be
missed with traditional GWAS or miR-SNP analysis.
In conclusion, this study provides evidence that pedMS risk is influenced by miRNAs acting on immune signaling and other genes, and several miRNA-target gene
pairs and specific tissues were nominated for further
study. Larger studies are needed to confirm these results,
and further work is needed to determine whether any
miRNA-mediated disease processes are specific to the
pediatric population.
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Figure S1. Multidimensional scaling plot of ped-MS cases
(black) and controls (gray) with ≥80% European ancestry
who were included in the GWAS, along with individuals
from the Human Genome Diversity Project.
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